Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec

Pharmaceutical Executive Daily: New Research on Ozempic

Today's Pharmaceutical Executive Daily covers key news in the pharmaceutical and life sciences industry.

FDA Approval of Bayer's Lynkuet

The FDA has approved Bayer's Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms associated with menopause.

New Research on Ozempic

New research suggests Ozempic may reduce biological age.

Novartis' Merger Agreement

Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.

No direct quote available in the given text.

Author's summary: New research on Ozempic and FDA approval of Lynkuet.

more

PharmExec PharmExec — 2025-10-28

More News